The success story of the transcatheter aortic valve replacement

It seems like the innovative non surgical technique of transcatheter aortic valve replacement heralds the start for radical changes in the field of valvular heart disease. Promising results from different clinical studys underline the positive impact.

Photo: The success story of the transcatheter aortic valve replacement

Replacing heart valves without the substantial trauma of opening the chest and the heart were little known concepts until the groundbreaking pulmonary and aortic transcatheter valve replacements performed during 2000 and 2002, respectively by Philipp Bonhoeffer and Alain Cribier. Today, advanced development programs for less invasive treatment of the aortic, mitral and pulmonary valves are coming to fruition and promises a period of great transformation in cardiovascular medicine both for patients and for their physicians.

Current experiences with one of the two CE Marked devices, the CoreValve ReValving® System for Percutaneous Aortic Valve Replacement (PAVR) have proved to be an overall success. This device consists of a porcine pericardial valve prosthesis mounted on a self-expanding Nitonol frame, which is delivered by means of an 18 French size (6mm) catheter. Today, the procedure can be performed in the cath lab by the interventional cardiologist under local anesthesia, without the use of surgical cut-down/repair (with pre-closing), without heart-lung bypass, and with the heart at normal sinus rhythm during valve placement.  
 
A first safety & efficacy study (August 2005 – August 2006) enrolled 65 patients. A second study (October 2006 – June 2007) enrolled 112 patients. The study criteria focused on severe aortic stenosis (AVAI≤0.6cm2/m2) in patients older than 75 years, or with Logistic EuroSCORE (LE) ≥15%, or older than 65 years with multiple co-morbidities. Endpoints considered procedural success/morbidity/mortality, as well as 30-day and long-term outcomes. 
 
Preliminary analysis of 175 patients enrolled in the combined studies (21F+18F) represent a combined mean theoretical surgical risk level of LE 24%, a mean age of 82 years, a mean pre-procedural AVA of 0.61cm2, and Mean Gradient (MG) 44.3mmHg. About one quarter of patients were deemed totally inoperable and 60% were female.   79% of patients were in NYHA class III/IV.
Overall procedural success was 91%. MG decreased to 7.9mmHg while AVA increased to 1.62cm2, with 86% of patients moving to NYHA class I/II. Procedural and procedure related mortality were

03.09.2008

More on the subject:

Related articles

Photo

Article • Generative AI

Large language models: enabler or eroder of cardiovascular care?

Large language models (LLMs) have potential in healthcare settings to help support both patients and clinicians. Cardiologist Dr Robert van der Boon believes they could have several applications,…

Photo

News • Study on ventricular shapes

How heart shape links to cardiovascular disease risk

Researchers have published findings that show the genetic structure of the heart’s shape may offer new insights into individual heart health.

Photo

News • Insights into bile production

Liver discovery could lead to better CVD treatments

A new discovery about how the liver flushes cholesterol from the body could lead to more effective treatments for cardiovascular disease – the leading cause of death worldwide.

Related products

Subscribe to Newsletter